Cargando…

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Efficacy of candidate antibacterial treatments must be demonstrated in animal models of infection as part of the discovery and development process, preferably in models which mimic the intended clinical indication. A method for inducing robust lung infections in immunocompetent rats and mice is desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoover, Jennifer L., Lewandowski, Thomas F., Mininger, Cindy L., Singley, Christine M., Sucoloski, Scott, Rittenhouse, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MyJove Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408714/
https://www.ncbi.nlm.nih.gov/pubmed/28117818
http://dx.doi.org/10.3791/55068
_version_ 1783232353736327168
author Hoover, Jennifer L.
Lewandowski, Thomas F.
Mininger, Cindy L.
Singley, Christine M.
Sucoloski, Scott
Rittenhouse, Stephen
author_facet Hoover, Jennifer L.
Lewandowski, Thomas F.
Mininger, Cindy L.
Singley, Christine M.
Sucoloski, Scott
Rittenhouse, Stephen
author_sort Hoover, Jennifer L.
collection PubMed
description Efficacy of candidate antibacterial treatments must be demonstrated in animal models of infection as part of the discovery and development process, preferably in models which mimic the intended clinical indication. A method for inducing robust lung infections in immunocompetent rats and mice is described which allows for the assessment of treatments in a model of serious pneumonia caused by S. pneumoniae, H. influenzae, P. aeruginosa, K. pneumoniae or A. baumannii. Animals are anesthetized, and an agar-based inoculum is deposited deep into the lung via nonsurgical intratracheal intubation. The resulting infection is consistent, reproducible, and stable for at least 48 h and up to 96 h for most isolates. Studies with marketed antibacterials have demonstrated good correlation between in vivo efficacy and in vitro susceptibility, and concordance between pharmacokinetic/pharmacodynamic targets determined in this model and clinically accepted targets has been observed. Although there is an initial time investment when learning the technique, it can be performed quickly and efficiently once proficiency is achieved. Benefits of the model include elimination of the neutropenic requirement, increased robustness and reproducibility, ability to study more pathogens and isolates, improved flexibility in study design and establishment of a challenging infection in an immunocompetent host.
format Online
Article
Text
id pubmed-5408714
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MyJove Corporation
record_format MEDLINE/PubMed
spelling pubmed-54087142017-05-12 A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii Hoover, Jennifer L. Lewandowski, Thomas F. Mininger, Cindy L. Singley, Christine M. Sucoloski, Scott Rittenhouse, Stephen J Vis Exp Infection Efficacy of candidate antibacterial treatments must be demonstrated in animal models of infection as part of the discovery and development process, preferably in models which mimic the intended clinical indication. A method for inducing robust lung infections in immunocompetent rats and mice is described which allows for the assessment of treatments in a model of serious pneumonia caused by S. pneumoniae, H. influenzae, P. aeruginosa, K. pneumoniae or A. baumannii. Animals are anesthetized, and an agar-based inoculum is deposited deep into the lung via nonsurgical intratracheal intubation. The resulting infection is consistent, reproducible, and stable for at least 48 h and up to 96 h for most isolates. Studies with marketed antibacterials have demonstrated good correlation between in vivo efficacy and in vitro susceptibility, and concordance between pharmacokinetic/pharmacodynamic targets determined in this model and clinically accepted targets has been observed. Although there is an initial time investment when learning the technique, it can be performed quickly and efficiently once proficiency is achieved. Benefits of the model include elimination of the neutropenic requirement, increased robustness and reproducibility, ability to study more pathogens and isolates, improved flexibility in study design and establishment of a challenging infection in an immunocompetent host. MyJove Corporation 2017-01-02 /pmc/articles/PMC5408714/ /pubmed/28117818 http://dx.doi.org/10.3791/55068 Text en Copyright © 2017, Journal of Visualized Experiments http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Infection
Hoover, Jennifer L.
Lewandowski, Thomas F.
Mininger, Cindy L.
Singley, Christine M.
Sucoloski, Scott
Rittenhouse, Stephen
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title_full A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title_fullStr A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title_full_unstemmed A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title_short A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
title_sort robust pneumonia model in immunocompetent rodents to evaluate antibacterial efficacy against s. pneumoniae, h. influenzae, k. pneumoniae, p. aeruginosa or a. baumannii
topic Infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408714/
https://www.ncbi.nlm.nih.gov/pubmed/28117818
http://dx.doi.org/10.3791/55068
work_keys_str_mv AT hooverjenniferl arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT lewandowskithomasf arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT miningercindyl arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT singleychristinem arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT sucoloskiscott arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT rittenhousestephen arobustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT hooverjenniferl robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT lewandowskithomasf robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT miningercindyl robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT singleychristinem robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT sucoloskiscott robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii
AT rittenhousestephen robustpneumoniamodelinimmunocompetentrodentstoevaluateantibacterialefficacyagainstspneumoniaehinfluenzaekpneumoniaepaeruginosaorabaumannii